Key facts
- This page summarizes Emma Reeve's Form 4 filing for CONSTELLATION PHARMACEUTICALS INC.
- 7 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 19 Jul 2021, 17:38.
Emma Reeve - 15 Jul 2021 Form 4 Insider Report for CONSTELLATION PHARMACEUTICALS INC
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 15 Jul 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Jul 2021, 17:38:22 UTC
- Next SEC filing
- 08 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Emma Reeve
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Emma Reeve filed Form 4 for CONSTELLATION PHARMACEUTICALS INC on 19 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNST
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -60,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 15 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- $36.06
- Footnotes
- F1
CNST
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -37,527
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 15 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,527
- Exercise price
- $11.50
- Footnotes
- F1
CNST
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -73,428
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 15 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 73,428
- Exercise price
- $8.76
- Footnotes
- F1
CNST
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -11,777
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 15 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,777
- Exercise price
- $8.04
- Footnotes
- F1
CNST
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -17,666
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 15 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,666
- Exercise price
- $7.60
- Footnotes
- F1
CNST
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -80,971
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 15 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,971
- Exercise price
- $6.61
- Footnotes
- F1
CNST
transaction
Derivative
Stock Options (Right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -66,950
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 15 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 66,950
- Exercise price
- $35.50
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Emma Reeve is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
SEC remarks
In connection with the consummation of the Merger, at the Effective Time, (a) immediately prior to the Effective Time, each outstanding Company stock option accelerated and became fully vested and exercisable; and (b) at the Effective Time, each unexercised outstanding Company stock option was cancelled in exchange for the right to receive a cash payment equal to the product of (i) the excess, if any, of the Merger Consideration, over the per share exercise price, and (ii) the number of shares of Common Stock subject to such Company stock option. Any company stock options that had an exercise price per share that was equal to or greater than the Merger Consideration was cancelled for no consideration.